ClinicalTrials.Veeva

Menu

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

A

ALX Oncology

Status and phase

Active, not recruiting
Phase 2

Conditions

Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma

Treatments

Drug: Cisplatin/Carboplatin; 5FU
Drug: pembrolizumab
Drug: evorpacept

Study type

Interventional

Funder types

Industry

Identifiers

NCT04675333
MK-3475-B88 (Other Identifier)
2020-004662-19 (EudraCT Number)
AT148004
KEYNOTE-B88 (Other Identifier)

Details and patient eligibility

About

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Full description

This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab + 5FU + platinum and of pembrolizumab + 5FU + platinum in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease. The study comprises of an initial safety lead-in followed by a randomized portion.

Enrollment

172 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Previously untreated metastatic or unresectable, recurrent head and neck squamous cell carcinoma.
  • Adequate bone marrow function.
  • Adequate renal and liver function.
  • Adequate ECOG performance status.

Exclusion criteria

  • Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
  • History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Prior treatment with any anti-CD47 or anti-SIRPα agent.
  • Prior treatment with anti-PD-1 or PD-L1.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

172 participants in 2 patient groups

evorpacept (ALX148) + pembrolizumab + Chemotherapy
Experimental group
Description:
evorpacept (ALX148) 45 mg/kg IV, pembrolizumab 200 mg IV, and chemotherapy given every 3 weeks.
Treatment:
Drug: evorpacept
Drug: pembrolizumab
Drug: Cisplatin/Carboplatin; 5FU
pembrolizumab + Chemotherapy
Active Comparator group
Description:
pembrolizumab 200 mg IV and chemotherapy given every 3 weeks.
Treatment:
Drug: pembrolizumab
Drug: Cisplatin/Carboplatin; 5FU

Trial contacts and locations

44

Loading...

Central trial contact

Harry Liu, MD, MPH, MBA; Richard J Morishige, MS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems